Wave Life Sciences Ltd. (WVE)
NASDAQ • Healthcare
Last close at September 9, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 9
in 60 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Wave Life Sciences’ earnings missed consensus in the second fiscal quarter of 2026, reported July 30, 2026, with EPS of -$0.34 trailing the -$0.30 estimate by -$0.04. The RNA medicines developer posted GAAP net income of -roughly $69.4 million, a -37% year-over-year move from about -$50.5 million a year ago, while operating income was -about $73.8 million. Operating cash flow was negative at around -$48.3 million. On the bottom line, EPS was down -9.7% year over year from -$0.31. Looking ahead, next-period consensus calls for EPS of -$0.33 on revenue of $5.0 million.
About Wave Life Sciences Ltd.
Wave Life Sciences Ltd. develops RNA medicines as a Biotechnology company in healthcare, with programs aimed at genetic, metabolic, and liver disorders. Listed on NASDAQ as WVE, it recorded $42.7 million of revenue in FY2025, and its pipeline centers on disease-specific candidates for rare inherited conditions, obesity, and other liver-related disorders.
Today's Snapshot
Yesterday WVE fell 2.0% to 4.81.
Trading Volume
Below 10d avg (3.6M)
3M
vs S&P 500 Today
Underperforming Market
-1.56%
Updated: September 10, 2026 at 12:09 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$4.95 - $8.03Sell
- RSI (14)38.26Neutral
- Stochastic %K (14, 3, 3)25.10Neutral
- MACD Level (12, 26)-0.23Sell
Peers & Related Assets
Get premium market insights delivered directly to your inbox.